We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 657

Vestager promotes fair play in tech at Web Summit
  • Freshfields Bruckhaus Deringer
  • European Union
  • November 17 2017

Fair competition in tech was given particular prominence at this year's Web Summit technology conference held in Lisbon on 6-9 November 2017. EU


Excessive Pricing - a New Lease of Life in Europe?
  • Hausfeld LLP
  • European Union
  • November 15 2017

While excessive pricing does not alone violate the U.S. antitrust laws., excessive pricing by dominant companies is subject to Article 102 of the


New Value-based Filing Thresholds in European Merger Control Regimes - Implications for Healthcare and Life Sciences Companies
  • Baker McKenzie
  • Austria, European Union, Germany
  • November 1 2017

Germany and Austria recently introduced new alternative merger control thresholds based on transaction value. At EU level the introduction of a


New value-based filing thresholds in European merger control regimes - implications for healthcare and life sciences companies
  • Baker McKenzie
  • Austria, European Union, Germany
  • October 17 2017

Germany and Austria recently introduced new alternative merger control thresholds based on transaction value. At EU level the introduction of a


Big fine for Facebook: what can healthcare companies do to avoid infringement errors during merger control?
  • Baker McKenzie
  • European Union
  • October 17 2017

The EUR 110 million fine imposed on Facebook confirms that the European Commission will not tolerate the supply of misleading or incorrect


What lessons and trends for EU merger control in healthcare can be learned from South Africa?
  • Baker McKenzie
  • European Union
  • October 17 2017

In July, the South African Competition Commission launched an investigation into Aspen, Pfizer and Roche in relation to alleged excessive pricing for


The Commission continues to rely on EU State aid rules to challenge EU tax regimes that grant benefits to companies
  • K&L Gates
  • European Union
  • October 2 2017

On 4 October 2017, the Commission found that Luxembourg had allegedly given illegal tax benefits to a US company operating an e-commerce platform


New value-based filing thresholds in European merger control regimes implications for healthcare and life sciences companies
  • Baker McKenzie
  • Austria, European Union, Germany
  • September 29 2017

Germany and Austria recently introduced new alternative merger control thresholds based on transaction value. At EU level the introduction of a


Excessive pricing enforcement action on the rise: a new enforcement trend?
  • Baker McKenzie
  • European Union
  • August 31 2017

Although enshrined in the EU treaties since inception, 'unfair pricing' as an abuse of market power was a little-used tool in enforcers' armoury


The Commission fines a leading IT company with a record EUR 2.42 billion fine for abuse of dominance
  • K&L Gates
  • European Union
  • August 30 2017

On 27 June 2017, the Commission announced it had concluded one of its investigations against a leading IT company ("Company") with the imposition of